Application of DHC (dehydrocorydaline) in preparation of preparation for treating atherosclerosis

Abstract

The invention discloses application of DHC (dehydrocorydaline) in preparation of a preparation for treating atherosclerosis. ApoE<- / ->mice prove that formation of atherosclerotic plaques treated by the DHC is reduced, the lesion area of the plaques is reduced, and it is indicated that DHC can relieve development of atherosclerosis. An oil red O staining result shows that the grease area of an administration group is reduced, F4 / 80 immunofluorescence staining shows that macrophage infiltration of the administration group is less, and a Masson staining result shows that the fiber collagen content of the administration group is higher, which indicates that the DHC can improve the stability of plaques. Administration of the DHC can also reduce systemic inflammation of atherosclerosis. An important scientific evidence is provided for potential application of the DHC as an atherosclerosis treatment or improvement agent.

Description

technical field [0001] The present invention relates to a new application of the compound, in particular to the application of DHC in the preparation of preparations for treating atherosclerosis. Background technique [0002] Cardiovascular disease (CVD), considered the greatest threat to human life and the leading cause of death worldwide, includes coronary artery disease (CAD), hypertension, cardiac arrhythmias, cardiomyopathy, and thromboembolism. Homeostasis of the cardiovascular system is maintained by interacting genetic and epigenetic programs, imbalances of which contribute to the pathogenesis of complex disease processes such as atherosclerosis and its life-threatening complications, stroke and myocardial infarction . Atherosclerosis is the most common pathological basis for coronary artery disease, peripheral arterial disease (PAD) and cerebrovascular disease, and is responsible for major mortality and morbidity from cardiovascular diseases, resulting in millions ...

AI Technical Summary

Problems solved by technology

In 1982, it was reported that DHC had a significant antispasmodic effect on coronary arteries. It was initially believed that DHC was the main component of Corydalis Corydalis in treating coronary heart disease. Later, in cardiovascular research, it was reported that DHC reduced the concentration of free calcium in cells and improved the self-activity of cardiomyocytes. Protective capacity, but little research on atherosclerosis

Images